Healthy Volunteer Study Using 3 Different Formulations of Firategrast

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 20, 2011

Primary Completion Date

September 17, 2011

Study Completion Date

September 17, 2011

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Firategrast immediate release tablet

Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.

DRUG

Firategrast modified release tablet

Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.

DRUG

Firategrast gastro-retentive solution

Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01416363 - Healthy Volunteer Study Using 3 Different Formulations of Firategrast | Biotech Hunter | Biotech Hunter